

# Myotonic Dystrophy Drug Development Pipeline - Feb. 2026

COMPANY	PROGRAM / LEAD CANDIDATE	MODALITY	DM SUBTYPE	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	DRUG TARGET / MECHANISM	PRESS RELEASES & MORE	MDF CONFERENCE INDUSTRY UPDATE	MDF MEET-THE-DM-DRUG-DEVELOPERS
<a href="#">AMO Pharma Ltd</a>	Tideglusib	Small Molecule	CDM / DM1					Glycogen synthase kinase 3 beta (GSK3B)	<a href="#">AMO Pharma News</a>	<a href="#">2024 Update</a>	<a href="#">2023 Webinar</a>
<a href="#">Avidity Biosciences</a>	AOC 1001 <i>del-desiran</i>	Antibody Conjugated Oligonucleotide	DM1					DMPK	<a href="#">Avidity News</a>	<a href="#">2025 Update</a>	<a href="#">2024 Webinar</a>
<a href="#">Lupin Neurosciences</a>	Mexiletine	Small Molecule	DM1 / DM2					Sodium Channels	<a href="#">Lupin News</a>	<a href="#">2025 Update</a>	<a href="#">2024 Webinar</a>
<a href="#">ARTHEX Biotech</a>	ATX-01	Antisense microRNA Oligonucleotide	DM1					MBNL via miR-23b	<a href="#">ARTHEX News</a>	<a href="#">2025 Update</a>	<a href="#">2024 Webinar</a>
<a href="#">Dyne Therapeutics</a>	Dyne 101 <i>z-basivarsen</i>	Antibody Fragment Conjugated Antisense Oligonucleotide	DM1					DMPK	<a href="#">Dyne News</a>	<a href="#">2025 Update</a>	<a href="#">2025 Webinar</a>
<a href="#">Harmony Biosciences</a>	Pitolisant	Small Molecule	DM1					Histamine-3 receptor (H3R)	<a href="#">Harmony News</a>	<a href="#">2023 Update</a>	<a href="#">2022 Webinar</a>
<a href="#">PepGen (University of Oxford Spinout)</a>	PGN-EDODM1	Peptide Conjugated Antisense Oligonucleotide	DM1					DMPK	<a href="#">PepGen News</a>	<a href="#">2025 Update</a>	<a href="#">2024 Webinar</a>
<a href="#">Juvena Therapeutics</a>	JUV-161	Stem Cell-Secreted Proteins	DM1					--	<a href="#">Juvena News</a>	<a href="#">2025 Update</a>	<a href="#">2024 Webinar</a>
<a href="#">Vertex</a>	VX-670	Peptide Conjugated Oligonucleotide	DM1					DMPK	<a href="#">Vertex News</a>	<a href="#">2025 Update</a>	
<a href="#">Sanofi</a>	--	miRNA Technology in Adeno-Associated Virus	--					DMPK	<a href="#">Sanofi News</a>	<a href="#">2025 Update</a>	
<a href="#">Sarepta</a>	SRP-1003	Investigational RNA interference (RNAi) Therapeutic	DM1					r(CUG) of DMPK	<a href="#">Sarepta News</a>		
<a href="#">ARTHEX Biotech</a>	ATX-01	Antisense microRNA Oligonucleotide	CDM / DM2					MBNL via miR-23b	<a href="#">ARTHEX News</a>	<a href="#">2025 Update</a>	<a href="#">2024 Webinar</a>
<a href="#">Arrakis Therapeutics</a>	--	RNA-targeted Small Molecule (rSM)	DM1					DMPK	<a href="#">Arrakis News</a>	<a href="#">2025 Update</a>	
<a href="#">Astellas Gene Therapies</a>	AT466	Adeno-Associated Viral Antisense	DM1					DMPK	<a href="#">Astellas News</a>		
<a href="#">Design Therapeutics</a>	DT818	Gene Targeting Chimera Small Molecule	DM1					r(CUG) of DMPK	<a href="#">Design News</a>		
<a href="#">EditForce, Inc.</a>	EF-210	Gene Transfer based Delivery of Pentatricopeptide Repeat Protein	DM1					r(CUG) of DMPK	<a href="#">EditForce News</a>		
<a href="#">GrittGene Therapeutics</a>	--	--	DM2					--	<a href="#">GrittGene Publications</a>	<a href="#">2022 Update</a>	
<a href="#">Kinea Bio, Inc.</a>	KNA-145; KNA-129	--	CDM / DM1					--	<a href="#">Kinea Bio News</a>		
<a href="#">LoQus23</a>	--	Small Molecule	DM1					MSH3	<a href="#">LoQus23 News</a>		
<a href="#">Modalis Therapeutics</a>	MDL-202	AAV mediated CRISPR base DMPK silencing	DM1					DMPK	<a href="#">Modalis News</a>	<a href="#">2025 Update</a>	
<a href="#">Novartis</a>	--	--	DM1					--	<a href="#">Novartis News</a>		
<a href="#">Rgenta Therapeutics</a>	RGT-DM1	Small Molecule	DM1					r(CUG) of DMPK	<a href="#">Rgenta News</a>	<a href="#">2023 Update</a>	

**Note:** Programs listed alphabetically by phase. Academic institutions are not included above. In addition to this list, there are several more companies in the Discovery Phase that have not yet made their DM programs public. [Click green arrows above for clinical trial information on Phases 1-3.](#) For locations and details of each clinical trial, visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Designed by MDF, this pipeline is in ongoing development and based on publicly available information. Special thanks to **Nate Uhl** for his comprehensive scan of the DM research landscape and original vision for the drug development pipeline. For questions, or to request updates to the pipeline, please contact MDF at [info@myotonic.org](mailto:info@myotonic.org). Download the latest DM Pipeline Chart at: [www.myotonic.org/pipeline](http://www.myotonic.org/pipeline).



# Archive of Past DM Drug Development Efforts - Feb 2026

Company / Organization	Company Status	DM Program	Notes
Anagenesis Biotechnologies	Closed	Unknown	Company closed in 2022; regenerative medicine focus included DM in early-stage research.
Arrowhead Pharmaceuticals	Active	Sold / Outlicensed	DM program acquired by Sarepta in 2025.
AskBio (Asklepios)	Active	Unknown	Gene therapy research for DM ended; company acquired by Bayer in 2020. Company operates as subsidiary of Bayer.
Audentes	Acquired	Active	Acquired by Astellas in 2020; DM programs carried forward into Astellas pipeline.
Biogen	Active	Unknown	Ionis partnership for antisense therapy ended after failed Phase I/II trial in 2015; published study.
BioMarin Pharmaceutical Inc.	Active	Unknown	Acquired Prosensa in 2014 with myotonic dystrophy program; no activity.
Celgene	Acquired	Unknown	Acquired by Bristol-Myers Squibb in 2019; historical DM relevance from investment in RNA-targeting companies.
CRISPR Therapeutics	Active	Active	Investigational in vivo gene-editing therapy for DM1 in collaboration with Vertex.
Cydan Development Inc.	Closed	Unknown	Company closed in 2021; rare disease accelerator; incubated companies with neuromuscular programs.
Denali Therapeutics	Active	Unknown	Ended DM program; initially pursued neuromuscular CNS-targeting therapeutics.
Dewpoint Therapeutics	Active	Unknown	Ended Pfizer-collaboration on DM program targeting toxic RNA condensates.
DTx Pharma	Acquired	Active	Acquired by Novartis in 2023; DM program ongoing within Novartis Gene Therapy.
Entrada	Active	Sold / Outlicensed	Outlicensed ENTR-670 and ENTR-701 program for DM1 to Vertex in 2023.
Enzerna Biosciences	Active	Unknown	Company inactive in practice; early RNA-targeting platform had DM relevance.
Expansion Therapeutics	Closed	Unknown	Company closed in 2025; small molecule DM1 program ended.
Faze Medicines	Closed	Unknown	Company closed in 2022; DM1 program targeted RNA repeat expansions.
Fortress Biotech & Oncogeny	Active	Unknown	Licensed Columbia University platform with potential DM applications in 2020; no disclosed program progress.
Fulcrum Therapeutics	Active	Unknown	No active DM program; past program on repeat expansion diseases suspended in 2024.

Company / Organization	Company Status	DM Program	Notes
Genethon	Active	Unknown	Rare disease gene therapy developer; early-stage DM1 research not advanced to pipeline.
Healx Ltd.	Active	Unknown	Ended DM program; focus shifted to other rare diseases.
Idera Pharmaceuticals / Aceragen	Active	Unknown	No active DM program; previously partnered with Scriptr Global for gene therapy research.
Ionis Pharmaceuticals (formerly ISIS Pharmaceuticals)	Active	Unknown	Biogen partnership for antisense therapy ended after failed Phase I/II trial in 2015; published study.
Kate Therapeutics	Acquired	Sold / Outlicensed	Acquired by Novartis in 2025; gene therapy focus in neuromuscular space included DM.
Locana Bio	Closed	Unknown	Company closed in 2023; Cas13d platform targeted DM1 RNA.
Myogem Health Company	Active	Unknown	Nutraceuticals marketed for DM symptom relief; no therapeutic development.
Neubase	Closed	Unknown	Company closed in 2024; proprietary RNA-targeting platform with DM1 program.
Nexien Biopharma	Active	Unknown	Program stopped; cannabinoid-based DM1 program.
Nymirum (Base4 Biotechnology)	Active	Unknown	Early-stage RNA-targeting biotech; no active DM program.
Pfizer	Active	Unknown	Ended DM program in 2021; past collaborations with Dewpoint and Triplet Therapeutics.
Prime Medicine	Active	Unknown	Ended DM program.
Roche	Active	Unknown	Early DM program exploration.
Sangamo	Active	Unknown	Ended gene regulation collaborations relevant to DM. Previous partnerships with Biogen and Novartis.
Syros Pharmaceuticals	Closed	Unknown	Closed in 2025.
Triplet Therapeutics	Closed	Unknown	Company closed in 2022; antisense therapy for repeat expansion diseases included DM. Former partnership with Pfizer.
Wave Life Sciences	Active	Unknown	Past DM1 interest; no current active program.
ScriptBiosciences	Closed	Unknown	Company closed in 2026. DM1 program targeted MSH3 CasPlusKO.
Scriptr Global, Inc.	Active	Unknown	DM1 program is no longer listed on website.